146k 1.9m...

146k
1.9m

https://hotcopper.com.au/documentdownload?id=uOMxKKzFkiWRTLKhOROKAxjvTDYC6ga4zhWZruJxke92GA==

Received 2 million in grants since September.

To bad the 1.9m won’t be in this coming quarterly, unless I’m mistaken.

Cash burn expected at 4.7m for the quarter. 8.3m in the bank... receipts? 1.6m me thinks.

My numbers 3.6m in, 4.7m out.

Looking forward to the results due for research into Autism...

https://hotcopper.com.au/documentdownload?id=uOMxKKzFkiWRTLKhOROKAxjvTDYC6g+0wBmZruJxke92GA==

From memory due Nov/Dec.

At the meeting Europe sales surpassing US sales. Japan going well.

As was explained in the meeting, in the USA customer has a tendency to buy, research, keep/return.
Europe research, buy, keep.
Setting up eye/hearing clinics in Europe seems a much more logical approach. Hence the Max.

Very interested to see receipt number trajectory. Specially since Japan came on board.

I wouldn’t like to see the company go full ball on Live production and go for CR at the end of it. If no OEM deal, I wouldn’t be surprised if Live sits in a shelf. We are in the health space after all. New catchphrase... GO MAX

JMT